← Back to Search

Virus Therapy

Gene Therapy + Chemoradiotherapy for Glioblastoma

Phase 1 & 2

Recruiting

Led By David S Baskin, MD

Research Sponsored by David Baskin MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have biopsy proven recurrent anaplastic astrocytoma or glioblastoma multiforme without evidence of multifocal tumor or brainstem involvement

Patients should have the following characteristics: recurrent glioblastoma or AA demonstrated by biopsy or imaging study, ECOG performance status of 0-1, has had prior surgery and radiotherapy/chemotherapy for the glioblastoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 60 months as measured in months

Awards & highlights

Study Summary

This trial is studying if a combination of HSV-tk gene therapy, valacyclovir, radiotherapy, and temozolomide is effective in treating patients with glioblastoma multiforme that has come back.

Who is the study for?

This trial is for adults with recurrent anaplastic astrocytoma or glioblastoma multiforme, confirmed by biopsy. Participants must have a life expectancy of at least 12 weeks, be recovered from previous treatments, and not have multifocal disease or brainstem involvement. They should use effective birth control and agree to provide biopsies. Those with other active cancers (except certain skin cancers), pregnant or breastfeeding women, and individuals unable to take oral medications are excluded.Check my eligibility

What is being tested?

The study tests the combination of HSV-tk gene therapy with valacyclovir medication, stereotactic body radiotherapy (SBRT), and chemotherapy in patients who have had their glioblastoma return. It aims to evaluate the safety and effectiveness of this approach.See study design

What are the potential side effects?

Potential side effects may include reactions related to gene therapy such as flu-like symptoms, issues from valacyclovir like headache or nausea, complications from radiotherapy including fatigue or skin irritation, and typical chemotherapy side effects like hair loss, nausea/vomiting, low blood counts leading to increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a confirmed diagnosis of recurrent anaplastic astrocytoma or glioblastoma without multiple tumor locations or brainstem involvement.

Select...

I have recurrent glioblastoma, can mostly care for myself, and had surgery and treatment before.

Select...

I am not pregnant or breastfeeding and have a recent negative pregnancy test.

Select...

I am using effective birth control methods.

Select...

My recent blood tests show my organs are functioning well.

Select...

I have no active cancer except for skin cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 60 months as measured in months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 60 months as measured in months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months as measured in months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Survival in months from Study drug administration (Day 0)

Secondary outcome measures

Progression Free Survival assessments will be done every 6-8 weeks for 1st year thereafter every 12-14 weeks until disease progression or death

Trial Design

1Treatment groups

Experimental Treatment

Group I: ADV/HSV-tk (gene therapy)Experimental Treatment1 Intervention

The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment. Patient can receive second treatment of HSV-tk after 6 months

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Center for Cell and Gene Therapy, Baylor College of MedicineOTHER

111 Previous Clinical Trials

2,755 Total Patients Enrolled

2 Trials studying Glioblastoma

18 Patients Enrolled for Glioblastoma

David Baskin MDLead Sponsor

David S Baskin, MDPrincipal InvestigatorHouston Methodist Neurological Institute

Media Library

ADV/HSV-tk (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03596086 — Phase 1 & 2

Glioblastoma Research Study Groups: ADV/HSV-tk (gene therapy)

Glioblastoma Clinical Trial 2023: ADV/HSV-tk Highlights & Side Effects. Trial Name: NCT03596086 — Phase 1 & 2

ADV/HSV-tk (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03596086 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment recruiting for participants?

"Affirmative. Per records on clinicaltrials.gov, the trial is currently enrolling participants; it was initially advertised on December 11th 2017 and last modified on September 3rd 2020. Specifically, 62 patients are being sought from a single medical centre."

Answered by AI

How many research subjects are taking part in this experiment?

"Affirmative. Information on clinicaltrials.gov confirms that the trial initiated on 12/11/2017 is actively accepting patients, with a goal of recruiting 62 individuals to 1 site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

David Baskin MD 2017. "HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03596086.

All > Glioblastoma Houston